Search Results

Paratek Pharmaceuticals, Inc. today announced that three new pre-clinical studies with NUZYRA ® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).

Paratek Pharmaceuticals, Inc. announced two key executive team promotions.

Paratek Pharmaceuticals, Inc. today announced that China’s National Healthcare Security Administration (NHSA) has added the oral formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia.

Paratek Pharmaceuticals, Inc. today announces that new data from NUZYRA ® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.

Gurnet Point Capital and Novo Holdings A/S announced the completion of their acquisition of Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.

Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announced positive top-line efficacy data for NUZYRA® as post-exposure prophylaxis in a non-human primate model of inhalational anthrax.

Paratek Pharmaceuticals, Inc. announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek’s special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings A/S.